share_log

Citizens Capital Markets Reiterates Market Outperform on Prelude Therapeutics, Maintains $4 Price Target

Benzinga ·  Mar 12 15:04

Citizens Capital Markets analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 233

Recommended

Write a comment